Evidence map›Paper›PMID 32188029›Full record

ArticleInternational journal of molecular sciences2020

Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS): A Multiplexed Microarray Platform for Targeted Proteomics.

Ghaith M Hamza, Vladislav B Bergo, Sergey Mamaev, Don M Wojchowski, Paul Toran, Camilla R Worsfold, M Paola Castaldi, Jeffrey C Silva

Registry-linked trialAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07505212 (Exploring Tannin-Probiotic Interactions on Microbial Composition and Inflammatory Outcomes in Obesity), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07505212 naactive not recruitingnot on this mapstarted 2026, after this paper: background citation

Exploring Tannin-Probiotic Interactions on Microbial Composition and Inflammatory Outcomes in Obesity

TypeinterventionalSponsorPrairie View A&M UniversityRan2026 to 2026Enrolled20ConditionsObesity (Disorder)ArmsGallotannin-rich mango, Lactiplantibacillus pentosus (probiotic), No Treatment Added
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. DNA Nanoarray for Multiplexed RNA Detection With Single-Molecule Readout.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Chemical biology approaches to study histone interactors.Biochemical Society transactions · 2021
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ghaith M HamzaDiscovery Sciences, BioPharmaceutical R&D, AstraZeneca, Boston, MA 02451, USA.
Vladislav B BergoAdeptrix Corporation, Beverly, MA 01915, USA.
Sergey MamaevAdeptrix Corporation, Beverly, MA 01915, USA.
Don M WojchowskiMolecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA.
Paul ToranMolecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA.
Camilla R WorsfoldAdeptrix Corporation, Beverly, MA 01915, USA.
M Paola CastaldiDiscovery Sciences, BioPharmaceutical R&D, AstraZeneca, Boston, MA 02451, USA.
Jeffrey C SilvaAdeptrix Corporation, Beverly, MA 01915, USA.

Funding

IN VITRO STUDIES OF ERYTHROPOIETIN ACTIONR01HL044491 · NHLBI · UNIVERSITY OF NEW HAMPSHIRE · PI WOJCHOWSKI, DON MICHAEL · 1991 to 2020
$4.8M
NHLBI NIH HHS R01 HL044491NIH HHS R01 HL044491
6 · The paper itself

Abstract

The ability to quantitatively probe diverse panels of proteins and their post-translational modifications (PTMs) across multiple samples would aid a broad spectrum of biological, biochemical and pharmacological studies. We report a novel, microarray analytical technology that combines immuno-affinity capture with Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS), which is capable of supporting highly multiplexed, targeted proteomic assays. Termed "Affinity-Bead Assisted Mass Spectrometry" (Affi-BAMS), this LC-free technology enables development of highly specific and customizable assay panels for simultaneous profiling of multiple proteins and PTMs. While affinity beads have been used previously in combination with MS, the Affi-BAMS workflow uses enrichment on a single bead that contains one type of antibody, generally capturing a single analyte (protein or PTM) while having enough binding capacity to enable quantification within approximately 3 orders of magnitude. The multiplexing capability is achieved by combining Affi-BAMS beads with different protein specificities. To enable screening of bead-captured analytes by MS, we further developed a novel method of performing spatially localized elution of targets from individual beads arrayed on a microscope slide. The resulting arrays of micro spots contain highly concentrated analytes localized within 0.5 mm diameter spots that can be directly measured using MALDI MS. While both intact proteins and protein fragments can be monitored by Affi-BAMS, we initially focused on applying this technology for bottom-up proteomics to enable screening of hundreds of samples per day by combining the robust magnetic bead-based workflow with the high throughput nature of MALDI MS acquisition. To demonstrate the variety of applications and robustness of Affi-BAMS, several studies are presented that focus on the response of 4EBP1, RPS6, ERK1/ERK2, mTOR, Histone H3 and C-MET to stimuli including rapamycin, H

Indexed as

ChromatinHumansHydrogen PeroxideIsotopesMicroarray AnalysisPeptide HydrolasesPoint MutationProtein Processing, Post-TranslationalProteinsProteomicsReproducibility of ResultsSensitivity and SpecificitySignal TransductionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationChromatinHydrogen PeroxideIsotopesPeptide HydrolasesProteinsBAMSbead assisted mass spectrometryMALDI MSmultiplex assaysPTMstargeted proteomics

Identifiers

PMID32188029
PMCPMC7139916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.